Serum hyaluronic acid is a useful marker of liver fibrosis in chronic hepatitis C virus infection

Patients with chronic hepatitis C virus (HCV) infection are often asymptomatic with few clinical signs of liver disease. Recognition of the presence of fibrosis or cirrhosis is difficult without liver biopsy, but with the availability of effective treatments, such as interferon, and the potential for progression to hepatoma in some cases, an accurate measure of the stage of disease is important. Serum hyaluronic acid (HA) has been identified as a potential marker of fibrosis or cirrhosis in other settings. In a prospective study in 130 chronic HCV carriers therefore, serum HA concentrations were compared with conventional liver function tests (including alanine aminotransferase (ALT), a‐glutathione‐S transferase (GST) and serum HCV RNA in order to determine which identified the stage of liver fibrosis as assessed by liver biopsy most accurately. The median HA concentrations according to the stage of fibrosis 0, 1&2, 3 and 4&5 were 17gl–1 (range 5– 37), 17gl–1 (5–80), 30gl–1 (10–105) and 350gl–1 (20–800) respectively. The median HA concentration in stage 4&5 was significantly greater than in stages 0, 1&2 or 3. Serum HA concentration rose with age, but even when adjusted for age the median HA at stage 4&5 was greater than all other groups (95% CI of difference between the medians exceeded 0). Thus, serum HA gave a sensitivity and specificity for stage 4&5 fibrosis of 85% and 88% respectively, exceeding those for ALT or GST. In contrast, serum ALT or GST levels were not correlated with the stage of fibrosis although ALT was significantly greater in the cirrhotic group when compared to the group with no fibrosis (stage 0). There was no correlation between serum HA and either the grade of inflammatory changes or serum HCV RNA. These results suggest that serum hyaluronic acid is a useful marker of liver fibrosis in patients with chronic HCV infection. It could therefore be used to monitor patients at risk of progressive fibrosis, in controlled clinical trials, as a measure of response to antifibrotic therapy and in those in whom liver biopsy is difficult or contraindicated.

[1]  T. Laurent,et al.  Plasma clearance, tissue distribution and metabolism of hyaluronic acid injected intravenously in the rabbit. , 1981, The Biochemical journal.

[2]  A. Engström‐Làurent,et al.  Removal of hyaluronic acid from the circulation in rheumatoid disease and primary biliary cirrhosis. , 1986, The Journal of laboratory and clinical medicine.

[3]  R. Chapman,et al.  Liver histology in hepatitis C infection: a comparison between patients with persistently normal or abnormal transaminases. , 1995, Gut.

[4]  A. Engström‐Làurent,et al.  Increased serum levels of hyaluronate in liver disease , 1985, Hepatology.

[5]  A. Alberti,et al.  Long-term follow-up of non-A, non-B (type C) post-transfusion hepatitis. , 1992 .

[6]  P. Simmonds,et al.  Chronic hepatitis in United Kingdom blood donors infected with hepatitis C virus , 1994, BMJ.

[7]  G. A. Rose.  Experiences with the use of interrupted carmine red and continuous chromium sesquioxide marking of human faeces with reference to calcium, phosphorus, and magnesium , 1964, Gut.

[8]  R. Wiesner,et al.  Serum type III procollagen peptide concentrations in severe chronic active hepatitis: Relationship to cirrhosis and disease activity , 1987, Hepatology.

[9]  A. Gressner.  Measurement of Connective Tissue Parameters in Serum for Diagnosis and Follow-Up of Liver Fibrosis , 1987, Annals of clinical biochemistry.

[10]  A. Gressner,et al.  Cellular Sources of Noncollagenous Matrix Proteins: Role of Fat-Storing Cells in Fibrogenesis , 1990, Seminars in liver disease.

[11]  A. Alberti,et al.  Hepatitis C viraemia and liver disease in symptom-free individuals with anti-HCV , 1992, The Lancet.

[12]  K. Murata,et al.  Polydispersity of acidic glycosaminoglycan components in human liver and the changes at different stages in liver cirrhosis. , 1985, Gastroenterology.

[13]  P. Gibson,et al.  Hemodynamic and liver function predictors of serum hyaluronan in alcoholic liver disease , 1992, Hepatology.

[14]  S. Kwok,et al.  Avoiding false positives with PCR , 1989, Nature.

[15]  K. Ishak,et al.  Histological grading and staging of chronic hepatitis. , 1995 .

[16]  N. F. Maclagan,et al.  The Mechanism and Interrelationships of the Flocculation Tests , 1952, Journal of clinical pathology.

[17]  T. Groth,et al.  A hyaluronan-loading test applied to patients with liver and joint diseases. , 1992, Clinica chimica acta; international journal of clinical chemistry.

[18]  T. Frebourg,et al.  Serum hyaluronate in liver diseases: Study by enzymoimmunological assay , 1986, Hepatology.

[19]  S. Schalm,et al.  Serial determination of type III procollagen amino propeptide serum levels in patients with histologically progressive and non-progressive primary biliary cirrhosis. , 1992, Journal of hepatology.

[20]  M. Houghton,et al.  Hepatitis C virus-specific CTL responses in the liver of chimpanzees with acute and chronic hepatitis C. , 1993, Journal of immunology.

[21]  K. Inokuchi,et al.  Epidemiology and long term prognosis of hepatitis C virus infection in Japan. , 1993, Gut.

[22]  S. Penman,et al.  New views of cell and tissue cytoarchitecture: Embedment‐free electron microscopy and biochemical analysis , 1985, Hepatology.

[23]  A. Engström‐Làurent,et al.  Serum hyaluronate in primary biliary cirrhosis—A biochemical marker for progressive liver damage , 1988, Hepatology.

[24]  B. Balkau,et al.  Relationship between procollagen III aminoterminal propeptide and hyaluronan serum levels and histological fibrosis in primary biliary cirrhosis and chronic viral hepatitis C. , 1994, Journal of hepatology.

[25]  M. Gardner,et al.  Confidence intervals rather than P values: estimation rather than hypothesis testing. , 1986, British medical journal.

[26]  M. Plebani,et al.  Biochemical markers of hepatic fibrosis. , 1991, Clinical biochemistry.

[27]  J. Spitzer,et al.  Gram‐negative bacterial lipopolysaccharide impairs hyaluronan clearance in vivo and its uptake by the isolated, perfused rat liver , 1993, Hepatology.

[28]  Gressner Am,et al.  Cellular sources of noncollagenous matrix proteins: role of fat-storing cells in fibrogenesis. , 1990 .